• Iptacopan (LNP023): Protocols and Troubleshooting in Complem

  2026-04-28

  Iptacopan (LNP023) enables precise, oral inhibition of complement factor B, transforming both in vitro and in vivo workflows for alternative pathway research. This guide delivers actionable protocol parameters, advanced troubleshooting, and evidence-backed insights to maximize reproducibility and translational impact.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-04-28

  CUDC-907 is a dual PI3K and HDAC inhibitor designed for in vitro research requiring simultaneous modulation of PI3K/AKT signaling and histone deacetylase activity. It is best suited for controlled cell-based workflows in oncology research and is not validated for diagnostic or therapeutic applications.

• AT13387: High-Performance Hsp90 Inhibitor for Cancer Biology

  2026-04-27

  AT13387 redefines Hsp90 inhibitor studies with its unique scaffold, nanomolar potency, and robust client protein degradation, streamlining apoptosis and cell cycle arrest workflows. This article delivers actionable protocol guidance, advanced troubleshooting, and a cross-domain perspective grounded in the latest research.

• RSL3 Glutathione Peroxidase 4 Inhibitor: Applied Cancer Rese

  2026-04-27

  RSL3, a potent glutathione peroxidase 4 inhibitor, is transforming ferroptosis-based cancer research with unprecedented selectivity and reproducibility. This article delivers actionable protocols, troubleshooting strategies, and advanced use-cases harnessing APExBIO’s RSL3 to model oncogenic RAS synthetic lethality and oxidative stress modulation.

• BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Guidan

  2026-04-26

  BFH772 is a potent, selective VEGFR2 inhibitor designed for researchers requiring precise modulation of VEGFR2-driven angiogenesis, particularly in tumor growth models. It is not suitable for workflows that demand water solubility or broad-spectrum kinase inhibition due to its defined solubility and selectivity properties.

• PD0325901: MEK Inhibitor Workflows for Precision Cancer Rese

  2026-04-25

  PD0325901 is a benchmark MEK inhibitor that enables precise dissection of the RAS/RAF/MEK/ERK pathway, supporting advanced studies in cancer cell signaling, apoptosis, and xenograft tumor suppression. This guide details optimized workflows, troubleshooting insights, and cross-study innovations to maximize PD0325901's research impact.

• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-04-24

  0.4% Trypan Blue Solution provides a reliable method for distinguishing live from dead cells in research workflows, supporting accurate cell viability measurement and cell counting. It is not suitable for diagnostic or clinical use and should only be applied within validated cell culture, viability, and cytotoxicity assay protocols.

• Norovirus Hijacks NINJ1 for Selective Viral Protein Secretio

  2026-04-24

  Song et al. reveal that murine norovirus (MNoV) co-opts the host protein NINJ1 to enable selective secretion of its NS1 protein, exploiting a regulated cell death pathway. This discovery clarifies mechanisms of unconventional protein secretion during viral infection and highlights new intersections between virology and programmed cell death.

• ML133 HCl: Potassium Channel Inhibitor for PASMC Research

  2026-04-23

  ML133 HCl stands out as a selective potassium channel inhibitor, enabling precise inhibition of Kir2.1 channels in pulmonary artery smooth muscle cell research. Leveraging robust selectivity and workflow-validated protocols, it empowers cardiovascular and vascular remodeling studies with high reproducibility and actionable insights.

• 17-AAG (Tanespimycin): Applied HSP90 Inhibition in Cancer Mo

  2026-04-23

  17-AAG (Tanespimycin) from APExBIO empowers researchers to achieve precise HSP90 chaperone inhibition and robust client protein degradation across diverse cancer models. This guide delivers stepwise workflows, advanced troubleshooting, and actionable insights—bridging foundational protocols with emerging discoveries in regulated cell death and membrane dynamics.

• Palonosetron Hydrochloride: Reliable 5-HT3 Antagonist for La

  2026-04-22

  This article presents scenario-driven insights for researchers using Palonosetron hydrochloride (SKU B2229) in cell viability and transporter assays. We address common experimental challenges, protocol optimization, and product selection, highlighting how APExBIO’s high-purity formulation ensures reproducibility and robust data for 5-HT3 receptor and transporter studies.

• Homoharringtonine: Mechanistic Innovation for Translational

  2026-04-22

  This thought-leadership article explores Homoharringtonine’s dual-action as a cytotoxic alkaloid, offering mechanistic insight and strategic guidance for translational researchers in cancer biology and antiviral studies. Highlighting its ribosomal inhibition, rapid SARS-CoV-2 clearance, and practical protocol parameters, the article contextualizes APExBIO’s Homoharringtonine (SKU N1504) as a uniquely validated research tool. By bridging competitive landscape analysis and workflow recommendations, it delivers actionable perspectives for the scientific community.

• Tubastatin A: HDAC6 Inhibition Redefines Translational Resea

  2026-04-21

  Tubastatin A, a highly selective HDAC6 inhibitor from APExBIO, is revolutionizing translational research by bridging epigenetic mechanisms, cell death modulation, and therapeutic innovation. This thought-leadership article integrates mechanistic insights, recent preclinical validation, and strategic guidance for researchers seeking to unlock new dimensions in cancer biology, neuroprotection, and inflammation. By contextualizing Tubastatin A’s unique capabilities within the evolving competitive landscape and referencing both landmark and emerging studies, we chart a path for rigorous, impactful experimentation and cross-domain discovery.

• Partial BACE1 Inhibition Spares Synaptic Function in AD Mode

  2026-04-21

  Satir et al. (2020) demonstrated that partial inhibition of beta-secretase (BACE1) can reduce amyloid-beta production by up to 50% without impairing synaptic transmission in neuron cultures. This study suggests that moderate BACE1 inhibition could be a strategic target for Alzheimer's disease research, balancing efficacy with synaptic safety.

• Norovirus Exploits NINJ1 for Selective Protein Secretion Con

  2026-04-20

  This study uncovers how murine norovirus hijacks the host protein NINJ1 to facilitate the selective secretion of its NS1 protein, a process critical for immune evasion. Using unbiased genetic screening and mechanistic analysis, the authors reveal new paradigms in regulated cell death, viral immune modulation, and unconventional protein secretion.

15580 records 1/1039 page Next 12345 下5页 Last page